Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans | Zendy

Changting Xiao | Zendy; Robert Bandsma | Zendy; Satya Dash | Zendy; Linda Szeto | Zendy; Gary F. Lewis | Zendy

Open Access

Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

Author(s) -

Changting Xiao,

Robert Bandsma,

Satya Dash,

Linda Szeto,

Gary F. Lewis

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.246207

Subject(s) - exenatide , agonist , glucagon like peptide 1 , endocrinology , glucagon like peptide 2 , medicine , receptor , glucagon like peptide 1 receptor , lipoprotein , peptide , chemistry , type 2 diabetes , diabetes mellitus , biochemistry , cholesterol

Incretin-based therapies for the treatment of type 2 diabetes mellitus improve plasma lipid profiles and postprandial lipemia, but their exact mechanism of action remains unclear. Here, we examined the acute effect of the glucagon-like peptide-1 receptor agonist, exenatide, on intestinal and hepatic triglyceride-rich lipoprotein production and clearance in healthy humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research